Most Read Articles
Stephen Padilla, 5 days ago
The novel coronavirus disease (COVID-19) pandemic appears to have a significant impact on oncological care, according to a study, which stresses the need for psycho-oncological support for cancer patients.
01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
5 days ago
Sodium–glucose cotransporter-2 (SGLT-2) inhibitors increase the risk for diabetic ketoacidosis (DKA) by almost threefold, with molecule-specific analyses suggesting a class effect, according to a study.
Stephen Padilla, Yesterday
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.

Dupilumab effective for chronic nodular prurigo

20 Jun 2020

Dupilumab is effective for reducing itch and improving skin lesions in patients with chronic nodular prurigo (CNPG), a new study has found.

Researchers conducted a retrospective multicentre analysis of 27 adult CNPG patients (mean age, 52.0±14.9 years; 16 women) who received 16 weeks of dupilumab treatment. Outcome measures included the numerical rating scale (NRS) for itch and sleeplessness, and the Investigator Global Assessment Scale (IGA).

Almost half of the participants had had a personal history of atopic dermatitis (AD) or other AD manifestations, and patients had had CNPG for an average of 13.7±13.6 years. All participants had previously been treated with at least one systemic treatment, and thirteen had failed at least three systemic treatments before dupilumab.

After 4 weeks of treatment, more than half of the patients showed a reduction in IGA score of at least two grades, and there were significant drops in itch and sleeplessness NRS scores (p<0.001). On the other hand, four patients dropped out at this point due to lack of efficacy or worsening CNPG.

Of the 23 remaining patients by week 16, 47.8 percent (n=11) were deemed to have very mild disease by IGA, while 21.7 percent (n=5) had mild disease. Nineteen participants (82.6 percent) achieved an 2-grade decrease in IGA.

Relative to baseline, itch NRS dropped from 8.9 to 2.7, while sleeplessness NRS decreased from 8.2 to 1.7 (p<0.001 for both). Ten patients were able to reach 36 weeks of treatment with sustained clinical efficacy.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 5 days ago
The novel coronavirus disease (COVID-19) pandemic appears to have a significant impact on oncological care, according to a study, which stresses the need for psycho-oncological support for cancer patients.
01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
5 days ago
Sodium–glucose cotransporter-2 (SGLT-2) inhibitors increase the risk for diabetic ketoacidosis (DKA) by almost threefold, with molecule-specific analyses suggesting a class effect, according to a study.
Stephen Padilla, Yesterday
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.